INmune Bio (INMB) Stock Price, Quote, News & History

Key Statistics

Open

$1.47

Volume / Avg.

187.00 / 400.60K

Day Range

- - -

52 Wk Range

1.38 - 11.64

Market Cap

$41.21M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

19.92%

Days to Cover

13.06

Recent INmune Bio Inc News

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Mohd Haider

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Vishaal Sanjay

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-30.65M

Investing Cash Flow (TTM)

Financing Cash Flow (TTM)

25.47M

Free Cash Flow (TTM)

-31.55M

Capital Expenditure (TTM)

Net Change in Cash (TTM)

-6.08M

Analyst Rating and Forecast

3.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$13.49M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

700.57

PB Ratio (TTM)

1.55

Earnings Yield % (TTM)

-140.54%

Earnings Yield % (FWD)

-66.55%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.95

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$2.50M

Total Cash

$27.73M

Debt to Equity

0.04

Issuance of Debt (TTM)

-$2.50M

Repayment of Debt (TTM)

-$2.50M

Key Statistics

Open

$1.47

Volume / Avg.

187.00 / 400.60K

Day Range

- - -

52 Wk Range

1.38 - 11.64

Market Cap

$41.21M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

19.92%

Days to Cover

13.06

About

Sector

Health Care

Industry

Biotechnology

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune,...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry